Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;43(12):1548-1553.
doi: 10.1177/10711007221119164. Epub 2022 Aug 29.

Comparing Rates of Fusion and Time to Fusion in Viable Cellular Allograft and Autograft

Robert M Frederick  1 , Shumaila Sarfani  2 , Chi-Yang Chiu  1 , Tristan Hayes  1 , Clayton Bettin  3 , Benjamin Grear  3 , David Richardson  3 , G Andrew Murphy  3
Affiliations

Comparing Rates of Fusion and Time to Fusion in Viable Cellular Allograft and Autograft

Robert M Frederick et al. Foot Ankle Int. 2022 Dec.

Abstract

Background: Autograft or allograft frequently are used to enhance bone union in foot and ankle surgery. Viable cellular bone allograft uses viable cells and bone scaffolding in a gel base, but uncertainty remains around allograft's greater efficacy than autograft regarding rates of fusion (ROF) and time to fusion (TTF).

Methods: Autograft, viable cellular allograft, and viable cellular allograft with autograft were compared in 199 forefoot, midfoot, and hindfoot arthrodeses performed over a 6-year period. Data collected from electronic medical records and radiographs were analyzed to determine ROF and TTF as well as rates of revision surgery for delayed or nonunion and compared among groups.

Results: Eighty-seven patients comprised the autograft group, 81 the allograft group, and 31 the combined group. No significant differences were noted in patient demographics among the groups. No statistically significant differences in ROF were noted among the 3 groups, with 86% (75 of 87) fusion in the autograft group, 93% (75 of 81) in the allograft group, and 84% (26 of 31) in the combined group (P = .20). After conducting a multivariate analysis, we found no statistically significant difference for allograft or combined graft on TTF (P = .1379 and .2311, respectively). No significant difference was found in rate of revision surgery for nonunion, which was 1.2% (1 of 81) in the allograft group, 3.4% (3 of 87) in the autograft group, and 6.5% (2 of 31) in the combined group (P = .3).

Conclusion: No significant difference was found in ROF, TTF, or rate of revision surgery when comparing viable cellular allograft to autograft or combined allograft-autograft. Viable cellular allograft may be a reasonable alternative to the gold standard of autograft and should be considered an option in patients undergoing arthrodesis in foot and ankle surgery.

Level of evidence: Level III, therapeutic.

Keywords: arthrodesis; autograft; bone union; cellular allograft; time to fusion.

PubMed Disclaimer

LinkOut - more resources